Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016–17 and 2017–18)

Esther Kissling, Marta Valenciano(World Health Organization), Mihaela Lazăr, Lisa Domegan(Health Service Executive), Caterina Rizzo(University of Pisa), Pasi Penttinen(European Centre for Disease Prevention and Control), Frederika Dijkstra(National Institute for Public Health and the Environment), Mia Brytting, Iwona Paradowska‐Stankiewicz(Narodowy Instytut Zdrowia Publicznego PZH – Państwowy Instytut Badawczy), Adam Meijer(National Centre for Infectious Diseases), Annamária Ferenczi(Semmelweis University), Antonino Bella(Istituto Superiore di Sanità), Sanja Filipović(Hrvatski zavod za javno zdravstvo), Francisco Pozo(Instituto de Salud Carlos III), Ralf Dürrwald(IDT Biologika (Germany)), Amparo Larrauri(Instituto de Salud Carlos III), Alin Gherasim(Instituto de Salud Carlos III), J Horváth(Semmelweis University), Katherina Zakikhany(Public Health Agency of Sweden), Ausenda Machado(National Institute of Health Dr. Ricardo Jorge), Vesna Višekruna Vučina(Hrvatski zavod za javno zdravstvo), Raquel Guiomar, Joan O’Donnell(Health Service Executive), Kari Johansen(European Centre for Disease Prevention and Control), Joanna Bogusz(Narodowy Instytut Zdrowia Publicznego PZH – Państwowy Instytut Badawczy), Ana‐Maria Vilcu(Inserm), Sylvie van der Werf(Centre National de la Recherche Scientifique), Daniela Pitigoi(Carol Davila University of Medicine and Pharmacy), Silke Buda(Robert Koch Institute)

Vaccine X

September 17, 2019

Cited by 36

Related Papers

|New England Journal of Medicine|2003|4.8k

|The Lancet|2003|1.1k

|The Lancet|2004|833

|Eurosurveillance|2020|715

|Frontiers in Public Health|2023|640